{"entity":{"id":"nct07722754","kind":"trial","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","aka":["BOND-4"],"tldr":"A phase 2 trial of cetuximab, fOLFIRI (5-FU, leucovorin, irinotecan), bevacizumab (glioblastoma use) and sintilimab in colorectal cancer, run by Guangdong Provincial People's Hospital, now recruiting.","summary":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial is a phase 2, randomised interventional study registered as NCT07722754 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 160 participants, started 2026-07-23 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cetuximab; Irinotecan; Bevacizumab; Sintilimab. Conditions listed: Colorectal Neoplasms Malignant; Neoplasm, Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: \"* Metastatic and unresectable colorectal adenocarcinom;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07722754","url":"https://clinicaltrials.gov/study/NCT07722754"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["cetuximab","folfiri","bevacizumab-glioma","sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07722754","phase":"2","setting":"A Randomized, Multi-center, Open-label Phase II Trial of Irinotecan and Cetuximab With or Without the Combination of Bevacizumab and Sintilimab in RAS Wild-type, Irinotecan-refractory Metastatic Colorectal Cancer","sponsor":"Guangdong Provincial People's Hospital","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07722754/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}